Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Study sponsor: Innate Pharma
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2012-07Actual
Enrollment · participants30Actual
Source updated2026-05-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.